Skip to Content
MilliporeSigma

UHPLC/MS Analysis of Antineoplastic and Antidepressant Drugs in Plasma on Titan C18 after SPE using HybridSPE®-PLus

UHPLC/MS Analysis of Antineoplastic and Antidepressant Drugs in Plasma on Titan™ C18 after SPE using HybridSPE®-PLus application for HPLC, application for SPE

Materials

SPE tube or plate

Product No.
Description
Pricing

HybridSPE®-PLus 96-Well Plate

volume 2 mL, pk of 1 ea

standard

Product No.
Description
Pricing

Tamoxifen

≥99%

Fluoxetine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

CONDITIONS

sample/matrix

rat plasma

SPE well plate

HybridSPE-PLus 96-Well Plate, 50 mg/2 mL per well (575659-U)

sample preparation

final analyte concentration 50 ng/mL

sample addition

400 μL of 1% formic acid acetonitile:spiked plasma (3:1) per well

column

Titan C18, 5 cm x 2.1 mm I.D., 1.9 μm particles (577122-U)

mobile phase

[A] 5 mM ammonium formate; [B] 5 mM ammonium formate in 90:10 (v:v) acetonitrile:water

gradient

35 to 90% B in 1.5 min, held at 90% B for 0.4 min

flow rate

0.4 mL/min

pressure

3582 psi (247 bar)

column temp.

35 °C

detector

TOF/MS

injection

1 μL

Description

Analysis Note

HybridSPE-Phospholipid plates removed plasma-derived proteins and phospholipids to maximize LC/MS sensitivity. Titan C18 U/HPLC columns provided rapid resolution. The highest grade LC-MS solvents were used to supply low background interference and low particulate contaminants for robust, trouble-free operation. Cerilliant CRMs provided reliable identification and quantification.

Legal Information

HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany
Titan is a trademark of Sigma-Aldrich Co. LLC